Article thumbnail

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells

By Benoit Tessoulin, Benoit Tessoulin, Benoit Tessoulin, Benoit Tessoulin, Geraldine Descamps, Geraldine Descamps, Geraldine Descamps, Christelle Dousset, Christelle Dousset, Christelle Dousset, Martine Amiot, Martine Amiot, Martine Amiot and Catherine Pellat-Deceunynck and Catherine Pellat-Deceunynck and Catherine Pellat-Deceunynck

Abstract

Prima-1Met (APR-246) was previously shown to be dependent on glutathione inhibition and on ROS induction in cancer cells with mutated or deleted TP53. Because this ROS induction was, at least in part, due to a direct interference with the thioredoxin reductase enzyme, we investigated whether activity of Prima-1Met could be mimicked by auranofin, an inhibitor of the thioredoxin reductase. We thus compared the activity of auranofin and Prima-1Met in 18 myeloma cell lines and in 10 samples from patients with multiple myeloma or plasma cell leukemia. We showed that, similar to Prima-1Met, the activity of auranofin was not dependent on either TP53 status or p53 expression; was inhibited by N-acetyl-L-cysteine, a ROS scavenger; displayed a dramatic synergy with L-buthionine sulfoximine, an irreversible inhibitor of glutathione synthesis; and induced cell death that was not dependent on Bax/Bak expression. These data showed that auranofin and Prima-1Met similarly overcome cell death resistance in myeloma cells due to either p53 deficiency or to mitochondrial dysfunction

Topics: Prima-1Met, APR-246, auranofin, ROS, venetoclax, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Publisher: Frontiers Media S.A.
Year: 2019
DOI identifier: 10.3389/fonc.2019.00128/full
OAI identifier: oai:doaj.org/article:3bacdfcf8c9b4a4e916a25e68db322e7
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://www.frontiersin.org/ar... (external link)
  • https://doaj.org/toc/2234-943X (external link)
  • https://doaj.org/article/3bacd... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles